Potential pathophysiological hypotheses include that the introduction of TNF alpha blockers may alter the cytokine balance in patients with a genetic predisposition, having genetic factors like NOD2/CARD15 gene mutations, which may result in background conditions for the development of IBD [3]. Here, NOD2 is linked to inflammatory bowel disease.